Explore 3 Stock Ideas & Industry Insights Download Free Report

Diaceutics PLC

Healthcare GB DXRX

144.0GBX
-9.0(5.88%)

Last update at 2026-06-04T15:29:00Z

Day Range

144.00155.00
LowHigh

52 Week Range

110.00176.25
LowHigh

Fundamentals

  • Previous Close 153.00
  • Market Cap140.06M
  • Volume175620
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA1.33M
  • Revenue TTM34.40M
  • Revenue Per Share TTM0.41
  • Gross Profit TTM 29.63M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.90800M -2.43800M 0.56M 0.46M -0.68200M
Minority interest - - - - -
Net income -1.70300M -1.74600M 0.72M 0.56M 0.26M
Selling general administrative 30.74M 22.78M 16.28M 10.38M 10.02M
Selling and marketing expenses - 4.77M - - -
Gross profit 28.27M 19.71M 16.74M 10.73M 9.46M
Reconciled depreciation 4.63M 4.77M 3.01M 1.80M 0.81M
Ebit -1.85400M -2.41400M 0.57M 0.55M -0.24300M
Ebitda 2.77M 2.36M 3.69M 2.35M 0.57M
Depreciation and amortization 4.63M 4.77M 3.12M 1.80M 0.81M
Non operating income net other - - - - -
Operating income -2.45500M -3.01800M 0.57M 0.55M -0.24300M
Other operating expenses 34.61M 26.72M 18.93M 13.39M 12.97M
Interest expense 0.05M 0.07M 0.12M 0.09M 0.04M
Tax provision -0.20500M -0.69200M -0.16000M -0.09900M -0.94500M
Interest income 0.60M 0.65M 0.11M 0.00000M 0.03M
Net interest income 0.55M 0.58M -0.01100M -0.08800M -0.01400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.20500M -0.69200M -0.16000M -0.09900M -0.94500M
Total revenue 32.16M 23.70M 19.50M 13.94M 12.70M
Total operating expenses 30.73M 22.72M 16.17M 10.18M 9.73M
Cost of revenue 3.89M 3.99M 2.76M 3.21M 3.23M
Total other income expense net 0.55M 0.58M -0.01100M -0.08800M -0.43900M
Discontinued operations - - - - -
Net income from continuing ops -1.70300M -1.74600M 0.72M 0.56M 0.26M
Net income applicable to common shares - - 0.72M 0.56M 0.26M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 48.62M 46.34M 48.26M 45.01M 43.52M
Intangible assets 15.41M 15.26M 15.22M 12.82M 9.36M
Earning assets - - - - -
Other current assets 1.82M 1.25M - 10.39M 8.36M
Total liab 8.76M 5.56M 5.74M 4.36M 3.28M
Total stockholder equity 39.86M 40.79M 42.51M 40.65M 40.24M
Deferred long term liab - - 0.18M 0.22M 0.42M
Other current liab 5.93M 2.29M 2.87M 1.84M 2.33M
Common stock 0.17M 0.17M 0.17M 0.17M 0.17M
Capital stock 0.17M 0.17M 0.17M 0.17M 0.17M
Retained earnings 40.62M 4.04M 5.34M 4.08M 3.19M
Other liab - - 0.79M 0.45M 0.37M
Good will - - - - -
Other assets - - 0.22M 0.22M 0.72M
Cash 12.74M 16.67M 19.84M 19.68M 25.25M
Cash and equivalents - - - - -
Total current liabilities 7.76M 4.38M 3.75M 2.63M 2.92M
Current deferred revenue - 0.41M - - -
Net debt -11.68400M -15.46200M -18.51200M -18.11400M -25.13700M
Short term debt 0.15M 0.15M 0.12M 0.28M 0.12M
Short long term debt - - 0.00000M 0.13M 0.12M
Short long term debt total 1.06M 1.21M 1.33M 1.56M 0.12M
Other stockholder equity -0.31200M 36.81M 37.00M 36.40M 36.88M
Property plant equipment - - 2.09M 2.13M 0.24M
Total current assets 29.53M 28.04M 30.90M 30.06M 33.62M
Long term investments - - - - -
Net tangible assets - - 27.47M 28.04M 31.30M
Short term investments - - - - -
Net receivables 14.96M 10.13M 5.79M 9.92M 7.78M
Long term debt - - - - -
Inventory - 0.00000M - - -
Accounts payable 1.22M 1.06M 0.76M 0.51M 0.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.62600M -0.24000M - - -0.15700M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.17M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 15.26M - - -
Deferred long term asset charges - - - - -
Non current assets total 19.09M 18.30M 17.36M 14.95M 9.90M
Capital lease obligations 1.06M 1.21M 1.33M 1.43M -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -4.03100M -4.20900M -4.75900M -5.60100M -6.29400M
Change to liabilities - - 1.27M -0.15900M -0.06300M
Total cashflows from investing activities -4.03100M -4.20900M -4.75900M -5.60100M -6.29400M
Net borrowings - - -0.16300M -0.10500M -0.10500M
Total cash from financing activities -0.06400M -0.23900M -0.19100M -0.27000M 19.61M
Change to operating activities - - - - -
Net income -1.90800M -1.74600M 0.56M 0.46M -0.68200M
Change in cash -3.92300M -3.17400M 0.17M -5.58000M 13.54M
Begin period cash flow 16.67M 19.84M 19.68M 25.25M 11.72M
End period cash flow 12.74M 16.67M 19.84M 19.68M 25.25M
Total cash from operating activities 0.65M 1.31M 5.10M 0.57M 0.25M
Issuance of capital stock 0.14M 0.00000M 0.13M 0.00000M 19.61M
Depreciation 4.63M 4.77M 3.01M 1.80M 0.81M
Other cashflows from investing activities -3.93100M -4.08400M 0.11M 0.11M 0.11M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -4.67600M -2.15800M -1.59400M -1.49900M 0.55M
Sale purchase of stock 0.00000M -0.04900M -0.09800M -0.16500M 19.61M
Other cashflows from financing activities -0.00100M -0.01100M -0.22200M -0.10500M -6.29400M
Change to netincome - - 1.69M -0.13200M -1.30500M
Capital expenditures 4.63M 4.86M 4.87M 5.60M 6.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.30200M -1.54000M -0.32800M -1.65800M 0.49M
Stock based compensation 1.02M 0.45M 0.54M 0.37M 0.29M
Other non cash items -1.78600M -0.62100M 1.32M 0.09M 0.02M
Free cash flow -3.98100M -3.54400M 0.23M -5.03100M -6.04100M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DXRX
Diaceutics PLC
-9.0 5.88% 144.00 - 178.57 4.07 3.51 3.53 35.21
CRW
Craneware Plc
58.00 3.88% 1554.00 29.63 11.26 2.36 1.84 2.89 9.61
OPT
Optima Health plc
-0.308 0.16% 186.69 15.04 13.59 1.42 0.96 1.52 10.54
KOO
Kooth plc
-2.75 1.74% 155.25 16.06 11.38 0.64 1.42 0.35 2.52
COG
Cambridge Cognition Holdings Plc
2.00 5.41% 39.00 - 12.84 2.01 7.68 2.10 100.23

Reports Covered

Stock Research & News

Profile

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

Diaceutics PLC

Building Two, Belfast, United Kingdom, BT9 6GW

Key Executives

Name Title Year Born
Mr. Peter Keeling Founder, CEO & Exec. Director 1962
Mr. Ryan Keeling Chief Innovation Officer & Exec. Director 1983
Mr. Nicholas Stewart Roberts CFO & Director 1983
Ms. Julie Browne Chief Operating Officer NA
Ms. Gillian Shaw Gen. Counsel NA
Ms. Jillian Beggs VP of Sales & Marketing NA
Ms. Norma Thompson Global Head of HR NA
Mr. Jordan Clark Chief Commercial Officer NA
Ms. Susanne Munksted Chief Precision Officer NA
Mr. Scott Morrison Head of Data Science NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.